Dermata Therapeutics Inc
$ 1.86
0.00%
29 Dec - close price
- Market Cap 1,909,200 USD
- Current Price $ 1.86
- High / Low $ 1.88 / 1.58
- Stock P/E 0.12
- Book Value 4.69
- EPS 15.24
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.96 %
- ROE -2.03 %
- 52 Week High 16.50
- 52 Week Low 1.58
About
None
Analyst Target Price
$10.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-13 | 2025-05-07 | 2025-03-17 | 2024-11-15 | 2024-08-15 | 2024-05-15 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-02-21 |
| Reported EPS | -1.65 | -2.67 | -1.2515 | -0.92 | -20.4 | -4.18 | -7.05 | -0.21 | -0.54 | -0.63 | -2.27 | -2.4 |
| Estimated EPS | -0.32 | -0.44 | -0.45 | -0.32 | -26.4 | -3.79 | -5.4 | -0.78 | -0.63 | -0.92 | -2.65 | -3.2 |
| Surprise | -1.33 | -2.23 | -0.8015 | -0.6 | 6 | -0.39 | -1.65 | 0.57 | 0.09 | 0.29 | 0.38 | 0.8 |
| Surprise Percentage | -415.625% | -506.8182% | -178.1111% | -187.5% | 22.7273% | -10.2902% | -30.5556% | 73.0769% | 14.2857% | 31.5217% | 14.3396% | 25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DRMA
2025-12-30 01:10:31
Dermata Therapeutics Inc. (NASDAQ:DRMA) stock surged 18.8% in after-hours trading after announcing the closure of a $4.1 million private placement. The company issued common stock and warrants, with insiders participating, and plans to use the proceeds for general corporate purposes including consumer research for its new OTC acne kit and potential acquisitions.
2025-12-30 01:10:31
Dermata Therapeutics (DRMA) secured approximately $3.7 million in net proceeds through multiple financing agreements related to a private placement. These agreements include a Securities Purchase Agreement with investors for common stock and warrants, a Registration Rights Agreement, and amendments to outstanding warrants. The funds are designated for general corporate purposes, including the launch of a new OTC acne kit and other strategic initiatives.
2025-12-30 01:06:31
Dermata Therapeutics announced the closing of a private placement, raising $4.1 million upfront by issuing shares and warrants, with potential for another $8.3 million if all warrants are exercised. Insiders participated in the offering, and proceeds will fund product launch activities for the company's new OTC acne kit, expected in mid-2026, and general corporate purposes. This financing is part of Dermata's strategic pivot to OTC dermatology, aimed at increasing liquidity and supporting its new acne treatment development.
2025-12-29 21:10:31
Dermata Therapeutics has closed a private placement totaling up to $12.4 million, with $4.1 million upfront and potential additional proceeds of $8.3 million from warrant exercises. The placement involves shares of common stock and accompanying warrants priced at-the-market under Nasdaq rules, with participation from company insiders. Proceeds will fund general corporate purposes, consumer research studies, and pre-launch/launch activities for their new OTC acne kit.
2025-12-25 02:09:35
Dermata Therapeutics (DRMA) stock surged 22% pre-market after the company announced positive topline results from its Phase 2 trial of DMT410. The study, testing DMT410 in adult patients with moderate-to-severe rosacea, met its primary endpoint for safety and tolerability.
2025-12-25 02:09:34
Dermata Therapeutics, Inc. has announced a private placement totaling up to $12.4 million, with $4.1 million upfront and an potential additional $8.3 million upon full exercise of warrants. This financing is priced at-the-market under Nasdaq rules. The announcement was made from San Diego, CA on December 24, 2025.
